CHROMEDX CORP.

CONDENSED UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTH PERIODS ENDED DECEMBER 31, 2017 AND 2016

INDEX

CHROMEDX CORP
MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING
DECEMBER 31, 2017

Notice of No Auditor Review of Condensed Interim Consolidated Financial Statements

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the interim financial statements; they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor. The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by management and approved by the Audit Committee and Board of Directors of the Company. The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

(UNAUDITED - Expressed in Canadian dollars)

As at		December 31, 2017		September 30, 2017
Assets				
Current assets				
Cash and cash equivalents	$	**1,464,318**	$	477,115
Accounts receivable		**50,000**		-
Prepaid expenses		**12,666**		8,704
HST receivable		**180,581**		116,034
		1,707,565		601,853
Non-current assets				
Reclamation bonds		**70,988**		70,988
Promissory note (note 7)		**59,429**		59,429
Patents (note 6)		**1,387,137**		1,550,493
	$	**3,225,119**	$	2,282,763
Liabilities				
Accounts payable and accrued liabilities	$	**127,180**	$	177,264
		127,180		177,264
Shareholders' equity				
Capital stock (note 8 (a))		**10,030,679**		8,368,737
Warrant reserve (note 8 (c))		**1,912,921**		1,614,113
Contributed surplus		**2,647,136**		1,850,809
Deficit		**(11,492,797)**		(9,728,160)
		3,097,939		2,105,499
	$	**3,225,119**	$	2,282,763

NATURE OF OPERATIONS AND GOING CONCERN, (Note 1)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

(UNAUDITED - Expressed in Canadian dollars)

		2017		2016
Expenses				
Management fees (note 9)	$	57,500	$	50,000
Consulting fees		480,759		248,732
Shareholder communications and marketing		121,463		15,000
Office, general and administrative		90,717		45,450
Professional fees		48,727		78,095
Patent amortization expense (note 6)		163,356		163,356
Share-based payments (note 8(b))		802,114		362,257
Transfer agent and filing fees		-		1,950
Net loss and comprehensive loss for the period	$	1,764,637	$	964,840
Loss per share				
Basic and diluted (note 12)	$	(0.02)	$	(0.02)
Weighted average number of common shares outstanding, basic and diluted		76,050,302		56,101,586

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

CHROMEDX CORP.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE THREE MONTH PERIODS ENDED DECEMBER 31, 2017 and 2016
(UNAUDITED - Expressed in Canadian dollars)

	Capital Stock		Warrant reserve	Contributed surplus	Deficit	Total
	Number of shares	Amount				
Balance - October 1, 2016	56,045,097	6,486,576	972,830	526,316	(5,847,763)	2,137,959
Shares issued for cash, net of issuance costs	5,627,000	716,949	-	-	-	716,949
Shares issued for cash on exercise of options	200,000	20,000	-	-	-	20,000
Shares issued for cash on exercise of warrants	474,000	94,800	-	-	-	94,800
Fair value of options exercised	-	23,148	-	(23,148)	-	-
Fair value of warrants issued, exercised and expired	-	(389,043)	389,043	-	-	-
Share-based payments	-	-	-	362,257	-	362,257
Net loss for the year	-	-	-	-	(964,840)	(964,840)
Balance - December 31, 2016	62,346,097	$ 6,952,430	$ 1,361,873	$ 865,425	$ (6,812,603)	$ 2,367,125
Balance - October 1, 2017	**72,054,764**	**8,368,737**	**1,614,113**	**1,850,809**	**(9,728,160)**	**2,105,499**
Shares issued for cash, net of issuance costs (note 8 (a))	**7,570,500**	**884,748**	**589,824**	**-**	**-**	**1,474,572**
Shares issued for cash on exercise of options (note 8 (b))	**50,000**	**5,000**	**-**	**-**	**-**	**5,000**
Shares issued for cash on exercise of warrants (note 8 (c))	**2,241,960**	**475,392**	**-**	**-**	**-**	**475,392**
Fair value of options exercised	**-**	**5,787**	**-**	**(5,787)**	**-**	**-**
Fair value of warrants exercised and expired	**-**	**291,015**	**(291,015)**	**-**	**-**	**-**
Share-based payments (note 8 (b))	**-**	**-**	**-**	**802,114**	**-**	**802,114**
Net loss for the year	**-**	**-**	**-**	**-**	**(1,764,637)**	**(1,764,637)**
Balance - December 31, 2017	**81,917,224**	**$ 10,030,679**	**$ 1,912,922**	**$ 2,647,136**	**$ (11,492,797)**	**$ 3,097,940**

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

CHROMEDX CORP.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTH PERIODS ENDED DECEMBER 31, 2017 and 2016
(UNAUDITED - Expressed in Canadian dollars)

	2017	2016
Operating activities		
Net loss	**$ (1,764,637)**	$ (964,840)
Add (deduct)		
Patent amortization expense	**163,356**	163,470
Share-based payments	**802,114**	362,257
Net decrease / (increase) in accounts receivable	**(50,000)**	(66,300)
Net decrease / (increase) in prepaid expenses	**(3,962)**	-
Net decrease / (increase) in HST receivable	**(64,547)**	(4,436)
Net (decrease) increase in accounts payables and accrued liabilities	**(50,084)**	(75,665)
Net cash used by operating activities	**(967,760)**	(585,514)
Investing activities		
Increase in reclamation bonds	**-**	(131)
Purchase of property and equipment	**-**	(1,763)
Repayment of promissory note	**-**	72,500
Cash provided by investing activities	**-**	70,606
Financing activities		
Issuance of common shares, net of issuance costs	**1,954,963**	831,749
Repayment to related party	**-**	(95,780)
Cash provided by financing activities	**1,954,963**	735,969
Increase in cash	**987,203**	221,061
Cash - beginning of year	**477,115**	5,162
Cash - end of year	**$ 1,464,318**	$ 226,223

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1. NATURE OF OPERATIONS AND GOING CONCERN

ChroMedX Corp. ("the Company") was incorporated in British Columbia and is engaged in the business of research, development and manufacturing of in vitro diagnostics and point-of-care technologies. The principal business address of the Company is 65 Queen Street West Suite 520, Toronto, Ontario, M5H 2M5.

The current market conditions and volatility increase the uncertainty of the Company's ability to continue as a going concern given the need to both manage expenditures and to raise additional funds. The Company is experiencing, and has experienced, negative operating cash flows and has working capital of $1,580,385 as at December 31, 2017 (September 30, 2017 - $424,589). The Company will continue to search for new or alternate sources of financing in order to continue development of its products but anticipates that the current market conditions may impact the ability to source such funds. These material uncertainties cast significant doubt on the Company's ability to continue as a going concern.

There can be no assurance that the Company will be able to continue to raise funds in which case the Company may be unable to meet its obligations. Should the Company be unable to realize on its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded on the consolidated statement of financial position.

On June 30, 2014, the Company entered into a share exchange agreement with ChroMedX Ltd. ("ChroMedX") pursuant to which the Company has acquired from the ChroMedX shareholders all of the issued and outstanding shares of ChroMedX in exchange for an equal number of common shares in the capital of the Company (the "Acquisition"). ChroMedX will be the registered holder of certain patents and patents pending in the biomedical technology field. Upon completion of the Acquisition, ChroMedX became a wholly-owned subsidiary of the Company, and Monarch Energy Limited changed its name to ChroMedX Corp. The Acquisition was accounted for as a reverse acquisition.

On January 31, 2017, the Company filed Articles of Amalgamation under the Business Corporations Act (Ontario), whereby the Company was amalgamated with ChroMedX to form an amalgamated corporation operating under the name of "ChroMedX Corp." (the "Company"). All amounts herein reflect the financial effects of the amalgamation.

2. BASIS OF PRESENTATION

These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC") which the Canadian Accounting Standards Board has approved for incorporation into Part 1 of the Handbook of Chartered Professional Accountants of Canada applicable to the preparation of interim financial statements, including International Accounting Standard ("IAS") 34, Interim Financial Reporting. These unaudited condensed interim consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements, and should be read in conjunction with the Company's annual consolidated financial statements as at and for the year ended September 30, 2017.

Principles of Consolidation

These consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, ChroMedX Ltd. prior to the amalgamation of its subsidiary (see Note 1). All significant intercompany balances and transactions have been eliminated on consolidation.

Basis of Measurement

These consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments which are measured at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

Functional and Presentation Currency

The consolidated financial statements are presented in Canadian dollars, which is also the Company's functional currency.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

These unaudited condensed interim consolidated financial statements, including comparatives, have been prepared following the same accounting policies and methods of computation as the audited annual consolidated financial statements for the year ended September 30, 2017.

4. SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES

The preparation of these condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. In preparing these condensed interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the Company’s annual consolidated financial statements for the year ended September 30, 2017.

5. RECENT ACCOUNTING PRONOUNCEMENTS

The following are future changes in accounting policies not yet effective as at September 30, 2017:

I. IFRS 9 - Financial Instruments - The standard was issued in its final version by the International Accounting Standards Board (“IASB”) in July 2014 bringing together the classification and measurement, impairment and hedge accounting phases of the IASB’s project to replace IAS 39, “Financial instruments: recognition and measurement” (“IAS 39”). The standard retains but simplifies the mixed measurement model and establishes two primary measurement categories for financial assets: amortized cost and fair value. The mandatory effective date of IFRS 9 is for annual periods beginning on or after January 1, 2018, with early adoption permitted. The Company is assessing the impact of this standard.

II. IFRS 15 - Revenue from Contracts with Customers – This standard was issued by the IASB on May 28, 2014, and amended on April 12, 2016, and will replace IAS 18, “Revenue”, IAS 11 “Construction Contracts”, and related interpretations on revenue. IFRS 15 sets out the requirements for recognizing revenue that apply to all contracts with customers, except for contracts that are within the scope of the standards on leases, insurance contracts and financial instruments. IFRS 15 uses a control based approach to recognize revenue which is a change from the risk and reward approach under the current standard. Companies can elect to use either a full or modified retrospective approach when adopting this standard and it is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. The Company is assessing the impact of this standard.

III. IFRS 16 – Leases – The standard was issued by the IASB on January 13, 2016, and will replace IAS 17, “Leases”. IFRS 16 will bring most leases on-balance sheet for lessees under a single model, eliminating the distinction between operating and financing leases. Lessor accounting however remains largely unchanged and the distinction between operating and finance leases is retained. The new standard is effective for annual periods beginning on or after January 1, 2019 with early adoption permitted if IFRS 15 has also been applied. The Company is assessing the impact of this standard.

(UNAUDITED - Expressed in Canadian dollars)

6. PATENTS

The following is a summary of patents as at December 31, 2017:

Balance - September 30, 2017	1,550,493
Amortization	(163,356)
Balance - December 31, 2017	**$ 1,387,137**

This asset relates to patents and a patent option which was granted by InvidX Corp ("InvidX") to the Company to acquire all rights, title and interest in and to the Patents, and was exercisable on or before 2 years following the date of the Option Agreement dated June 16 2014. In consideration of the option granted, the Company issued 15,000,000 common shares in the capital of the Company as of June 16, 2014. The Company had the option during the 2 year period for a purchase of $1,500,000, such purchase price to be satisfied either by a cash payment or through the issuance of common shares of the Company at a minimum price of 20% discount to the 10-day volume weight average trading price of the Company's common shares immediately preceding the exercise of the option.

At the time of the acquisition of the option, InvidX was a shareholder in ChromedX Ltd. and was operating as ChromedX Inc. Subsequent to the reverse takeover, ChromedX Inc. changed its name to InvidX Corp. InvidX is controlled by an officer of the Company.

On December 9, 2014, the Company exercised the option and in consideration, issued 5,474,452 common shares to InvidX Corp.

7. PROMISSORY NOTE

During the year ended September 30, 2016, the Company entered into a promissory note agreement in the amount of $250,000 for the amount outstanding in the previous year from a shareholder, which has been paid down to $59,429 as at December 31, 2017. The loan bears interest at the Bank of Montreal prime rate plus 1% per annum and the principal and interest are due on demand.

8. CAPITAL STOCK

(a) **Common shares**

Authorized

The authorized capital stock of the Company consists of an unlimited number of common shares.

Issued and Outstanding

	Number	Amount
Balance - September 30, 2017	**72,054,764**	**$ 8,368,737**
Shares issued on financing (i)	7,570,500	884,748
Shares issued on exercise of stock options (b)	50,000	5,000
Shares issued on exercise of warrants (c)	2,241,960	475,392
Balance - December 31, 2017	**81,917,224**	**$ 9,253,485**

i. On November 20, 2017, the Company closed a non-brokered private placement of 7,570,500 units at a price of $0.20 per unit for aggregate gross proceeds of $1,514,100. Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of $0.30 for a period of two years. Certain eligible persons were paid a cash commission equal to 8% of the proceeds raised from subscribers introduced to the Company by such persons, and also issued broker warrants equal to 8% of the securities purchased by such subscribers. Each broker warrant entitles the holder thereof to purchase one common share at a price of $0.20 for a period of two years. All securities issued are subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation

(UNAUDITED - Expressed in Canadian dollars)

(b) Stock option plan and share-based payments

The Company has a stock option plan under which it is authorized to grant options to directors, employees and consultants enabling them to acquire up to 20% of the issued and outstanding common shares of the Company. Under the plan, the exercise price of each option equals the market price, minimum price, or a discounted price of the Company's shares as calculated on the date of grant. The options can be granted for a maximum term of 10 years.

The following table summarizes information concerning the Company's stock options outstanding as at December 31, 2017:

Three months ended December 31, 2017	Number of Options Outstanding	Black-Scholes Value	Weighted Average Exercise Price
Balance - September 30, 2017	9,730,000	1,842,506	0.22
Granted	3,212,000	802,114	0.27
Exercised	(50,000)	(5,787)	0.10
Expired	(600,000)	(81,460)	0.10
Balance - December 31, 2017	**12,292,000**	**$ 2,557,373**	**$ 0.23**

The following common share purchase options are outstanding at December 31, 2017:

Date of Grant	Number of Options Outstanding	Exercise Price	Weighted Average remaining life (years)	Expiry Date	Number of Options exercisable
July 10, 2014	1,350,000	0.10	-	July 10, 2019	1,350,000
December 10, 2014	550,000	0.35	-	December 10, 2019	550,000
December 7, 2015	620,000	0.20	1.94	December 7, 2020	620,000
October 24, 2016	2,800,000	0.15	2.94	October 24, 2021	2,800,000
June 19, 2017	3,760,000	0.30	3.82	June 19, 2022	3,760,000
November 20, 2017	3,212,000	0.27	4.47	June 19, 2022	3,212,000
	12,292,000				**12,292,000**

The weighted average share price on the date options were exercised was $0.63.

(UNAUDITED - Expressed in Canadian dollars)

The fair value of options granted during the three months ended December 31, 2017 was estimated at the date of grant using a Black Scholes Option Pricing Model with the following assumptions:

For the three months ended	December 31, 2017
Share price	$0.27
Risk-free interest rate	1.46%
Expected life of options	5 years
Annualized volatility	110%
Dividend rate	Nil
Forfeiture rate	0%

In the consolidated statements of loss and comprehensive loss, the Company recorded share-based payments of $802,114 for the three months ended December 31, 2017 (2016 - $362,257).

(c) **Warrants**

The following table summarizes warrants that have been issued, exercised or have expired during the three months ended December 31, 2017:

Three months ended December 31, 2017	Number of Warrants Outstanding	Black-Scholes Value	Weighted Average Exercise Price
Balance - September 30, 2017	14,693,627	540,875	0.23
Granted	7,768,140	589,825	0.30
Exercised	(2,241,960)	(133,302)	0.21
Expired	(1,990,000)	(157,713)	0.30
Balance - December 31, 2017	**18,229,807**	**$ 839,684**	**$ 0.26**

The weighted average share price on the date warrants were exercised was $0.75.

The fair value of options granted during the three months ended December 31, 2017 was estimated at the date of grant using a Black Scholes Option Pricing Model with the following assumptions:

For the three months ended	December 31, 2017
Share price	$0.27
Risk-free interest rate	1.46%
Time to maturity	2.0
Estimated volatility in the market price of the common shares	117%
Dividend yield	NIL

At December 31, 2017, the following warrants were outstanding. The warrants entitle the holders to purchase the stated number of common shares at the exercise price on or before the expiry date:

(UNAUDITED - Expressed in Canadian dollars)

Number of Warrants Outstanding	Exercise Price	Fair Value	Expiry Date
3,640,000	0.20	159,161	April 24, 2018
1,127,000	0.20	65,366	June 29, 2018
2,836,667	0.20	166,750	August 2, 2018
2,830,000	0.30	198,550	December 19, 2018
28,000	0.20	5,116	December 19, 2018
7,570,500	0.30	554,684	November 19, 2019
197,640	0.20	35,140	November 19, 2019
$18,229,807		$1,184,767	

9. RELATED PARTY TRANSACTIONS

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities:

As at December 31, 2017, amounts due to related parties consist of $NIL (September 30, 2017 - $NIL) to companies controlled by officers and directors of the Company.

10. FINANCIAL RISK FACTORS

The Company manages its exposure to a number of different financial risks arising from its operations as well as its use of financial instruments including market risks (commodity prices, foreign currency exchange rate and interest rate), credit risk and liquidity risk through its risk management strategy. The objective of the strategy is to support the delivery of the Company's financial targets while protecting its future financial security and flexibility.

Financial risks are primarily managed and monitored through operating and financing activities and, if required, through the use of derivative financial instruments. The financial risks are evaluated regularly with due consideration to changes in the key economic indicators and up-to-date market information.

The Company's financial instruments consist of cash and cash equivalents, reclamation bonds, promissory note, accounts payable and accrued liabilities, and amounts due to related parties. The fair value of the Company's accounts payable and accrued liabilities, and amounts due to related parties approximate their carrying value, due to their short-term maturities or ability of prompt liquidation. The Company's cash and cash equivalents are recorded at fair value, under the fair value hierarchy, based on level one quoted prices in active markets for identical assets or liabilities. The Company's other financial instruments, being reclamation bonds and promissory note, are measured at amortized cost.

The Company is exposed in varying degrees to a variety of financial instrument related risks.

Market Risk

Market risk is the risk or uncertainty arising from possible market price movements and their impact on the future performance of the business. These market risks are evaluated by monitoring changes in key economic indicators and market information on an on-going basis.

a) Interest Rate Risk

The Company has cash balances and a promissory note receivable, and is not at a significant risk to fluctuating interest rates. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. As of December 31, 2017, the Company did not have any investments in investment-grade short-term deposit certificates. The Company has a promissory note receivable that bears a fluctuating interest rate. The Company monitors the credit worthiness of the debtor and is satisfied with the debtor's ability to repay the amount owing.

b) Foreign currency risk

As at December 31, 2017, the Company's expenditures are predominantly in Canadian dollars, and any future equity raised is expected to be predominantly in Canadian dollars and therefore is not at a significant risk to fluctuating exchange risks.

Liquidity Risk

Liquidity risk encompasses the risk that a company cannot meet its financial obligations in full. The Company's main source of liquidity is derived from its common stock issuances. These funds are primarily used to finance working capital, operating expenses, capital expenditures, and acquisitions.

The Company manages its liquidity risk by regularly monitoring its cash flows from operating activities and holding adequate amounts of cash and cash equivalents.

As at December 31, 2017, the Company held cash of $1,464,318 (September 30, 2017 - $477,115) to settle current liabilities of $127,180 (September 30, 2017 - $177,264). All of the Company's liabilities are due within the next fiscal year. See note 1 for discussion on going concern.

Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents. The Company has reduced its credit risk by investing its cash equivalents with Canadian chartered banks.

11. CAPITAL MANAGEMENT

The Company defines capital management in the manner it manages its capital stock. As at December 31, 2017 the Company's capital stock was $10,030,679 (September 30, 2017 - $8,368,737).

There were no changes in the Company's approach to capital management during the three months ended December 31, 2017 and the Company is not subject to any externally imposed capital requirements.

The Company's objectives when managing capital are:

a) To safeguard the Company's financial capacity and liquidity for future earnings in order to continue to provide an appropriate return to shareholders and other stakeholders;

b) To maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk; and

c) To enable the Company to maximize growth by meeting its capital expenditure budget, to expand its budget to accelerate projects, and to take advantage of acquisition opportunities.

The Company's capital structure includes components of shareholders' equity.

The Company regularly monitors and reviews the amount of capital in proportion to risk and future development and exploration opportunities. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new debt or equity or similar instruments, reduce debt levels from, or make adjustments to, its capital expenditure program.

12. BASIC AND DILUTED LOSS PER SHARE

Basic loss per share has been calculated by dividing the net loss per the financial statements by the weighted average number of shares outstanding during the year. The fully diluted loss per share would be calculated using a common share balance increased by the number of common shares that could be issued on the exercise of outstanding warrants and options of the Company. As the Company is in a loss position for the three months ended December 31, 2017, this would be anti-dilutive.

]